After signing up, you'll start to receive regular news updates from us.
Imaxio Sells Genomics Division to Hybrigenics
Complete the form below to unlock access to ALL audio articles.
The work is based on proprietary IMX313 antigen re-engineering technology, which aims to create a significant improvement in the immunogenicity and therefore the effectiveness of each vaccine in which it is used.
“There is a major need to improve the efficacy of vaccine candidates in human and animal health. We will rise to this challenge by focusing on the development of our IMX313 technology,” said Alexandre le Vert, chief executive officer of Imaxio. “IMX313 may resolve the problems of developing vaccines and immunotherapies for key therapeutic indications such as tuberculosis, staphylococcal infection, influenza and malaria.”
Imaxio recently initiated a Phase I clinical trial of IMX313 in tuberculosis and is one of the coordinators of the EU-funded Bellerophon project to develop a vaccine against Staphylococcus aureus.
In France Imaxio already markets Spirolept(R), a human vaccine indicated for preventing a work-related infectious disease, and Trolovol(R), an orphan drug indicated for a congenital metabolic disease. These core biopharmaceutical products generated revenue of EUR 2.1 million in 2012, providing significant financial support for the continuation of R&D activity.
The financial terms of the agreement were not disclosed.
